| Autor: |
Karami Fath, Mohsen, Babakhaniyan, Kimiya, Anjomrooz, Mehran, Jalalifar, Mohammadrasoul, Alizadeh, Seyed Danial, Pourghasem, Zeinab, Abbasi Oshagh, Parisa, Azargoonjahromi, Ali, Almasi, Faezeh, Manzoor, Hafza Zahira, Khalesi, Bahman, Pourzardosht, Navid, Khalili, Saeed, Payandeh, Zahra |
| Předmět: |
|
| Zdroj: |
Vaccines; Sep2022, Vol. 10 Issue 9, p1448-N.PAG, 40p |
| Abstrakt: |
Glioblastoma (GBM) is the most typical and aggressive form of primary brain tumor in adults, with a poor prognosis. Successful glioma treatment is hampered by ineffective medication distribution across the blood-brain barrier (BBB) and the emergence of drug resistance. Although a few FDA-approved multimodal treatments are available for glioblastoma, most patients still have poor prognoses. Targeting epigenetic variables, immunotherapy, gene therapy, and different vaccine- and peptide-based treatments are some innovative approaches to improve anti-glioma treatment efficacy. Following the identification of lymphatics in the central nervous system, immunotherapy offers a potential method with the potency to permeate the blood-brain barrier. This review will discuss the rationale, tactics, benefits, and drawbacks of current glioma therapy options in clinical and preclinical investigations. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
